End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.33 CNY | +2.06% |
|
+5.04% | -7.09% |
01-29 | BCHT Biotechnology to Acquire 33% of Chuanxin Biopharma | MT |
10-25 | Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2024 | CI |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Assets | ||||||
Cash And Equivalents | 273M | 310M | 1.16B | 867M | 442M | |
Total Cash And Short Term Investments | 273M | 310M | 1.16B | 867M | 442M | |
Accounts Receivable, Total | 331M | 733M | 764M | 968M | 1.57B | |
Other Receivables | - | - | - | - | - | |
Total Receivables | 331M | 733M | 764M | 968M | 1.57B | |
Inventory | 86.47M | 146M | 241M | 192M | 199M | |
Prepaid Expenses | 17.93K | - | - | 100K | 924K | |
Other Current Assets, Total | 16.58M | 32.2M | 29.15M | 30.81M | 35.26M | |
Total Current Assets | 707M | 1.22B | 2.19B | 2.06B | 2.24B | |
Gross Property Plant And Equipment | 783M | 987M | 1.68B | 1.92B | 2.42B | |
Accumulated Depreciation | -165M | -204M | -241M | -280M | -330M | |
Net Property Plant And Equipment | 618M | 783M | 1.44B | 1.64B | 2.09B | |
Long-term Investments | 7.3M | 10.23M | 69.12M | 61.28M | 208M | |
Other Intangibles, Total | 74.74M | 249M | 224M | 204M | 347M | |
Deferred Tax Assets Long-Term | 9.05M | 20.96M | 31.93M | 54.2M | 90.97M | |
Deferred Charges Long-Term | 144M | 122M | 159M | 211M | 29.26M | |
Other Long-Term Assets, Total | 23.34M | 61.85M | 61.95M | 53.06M | 41.06M | |
Total Assets | 1.58B | 2.47B | 4.17B | 4.28B | 5.05B | |
Liabilities | ||||||
Accounts Payable, Total | 16.55M | 34M | 63.91M | 24.8M | 17.49M | |
Accrued Expenses, Total | 330M | 494M | 423M | 341M | 553M | |
Short-term Borrowings | 165M | - | - | - | 20.47M | |
Current Income Taxes Payable | 1.66M | 18.24M | - | 5.07M | 48.89M | |
Unearned Revenue Current, Total | - | 6.25M | 10.21M | 8.65M | 283K | |
Other Current Liabilities | 47.81M | 127M | 252M | 337M | 375M | |
Total Current Liabilities | 561M | 680M | 749M | 717M | 1.01B | |
Unearned Revenue Non Current | 9.18M | 7.88M | 8.09M | 5.92M | 9.86M | |
Deferred Tax Liability Non Current | - | - | - | 1.11M | 981K | |
Other Non Current Liabilities | - | - | 253K | 307K | 173K | |
Total Liabilities | 570M | 688M | 757M | 724M | 1.03B | |
Common Stock, Total | 130M | 372M | 413M | 413M | 413M | |
Additional Paid In Capital | 77.75M | 416M | 1.77B | 1.78B | 1.82B | |
Retained Earnings | 835M | 1.02B | 1.24B | 1.38B | 1.82B | |
Comprehensive Income and Other | -29.56M | -30.89M | -5.75M | -10.96M | -31.86M | |
Total Common Equity | 1.01B | 1.78B | 3.42B | 3.56B | 4.02B | |
Total Equity | 1.01B | 1.78B | 3.42B | 3.56B | 4.02B | |
Total Liabilities And Equity | 1.58B | 2.47B | 4.17B | 4.28B | 5.05B | |
Supplemental Items | ||||||
ECS Total Shares Outstanding on Filing Date | 362M | 372M | 413M | 413M | 413M | |
ECS Total Common Shares Outstanding | 362M | 372M | 413M | 413M | 413M | |
Book Value / Share | 2.8 | 4.79 | 8.28 | 8.62 | 9.74 | |
Tangible Book Value | 938M | 1.53B | 3.19B | 3.36B | 3.67B | |
Tangible Book Value Per Share | 2.59 | 4.12 | 7.74 | 8.13 | 8.9 | |
Total Debt | 165M | 0 | 0 | 0 | 20.47M | |
Net Debt | -108M | -310M | -1.16B | -867M | -422M | |
Debt Equivalent Oper. Leases | 9M | 10.59M | - | 11.73M | 11.73M | |
Equity Method Investments, Total | - | 4.26M | 35.88M | 34.17M | 34.86M | |
Account Code - Inventory Valuation | - | 6 | 6 | 6 | 6 | |
Inventories - Raw Materials, Total | 44.5M | 78.9M | 148M | 105M | 81.68M | |
Inventories - Work In Process, Total | 19.32M | 27.24M | 27.08M | 43.44M | 51.76M | |
Inventories - Finished Goods, Total | 25M | 40.05M | 138M | 85.22M | 92.2M | |
Buildings, Total | 346M | 325M | 308M | 375M | 488M | |
Machinery, Total | 399M | 426M | 452M | 510M | 826M | |
Full Time Employees | - | 1.05K | 1.23K | 1.25K | 1.24K | |
Accumulated Allowance for Doubtful Accounts (Supple) | - | - | 19.89M | 28.75M | 60.36M |